Chronic pain clinical trials in Kelowna, British Columbia

Part of chronic pain trials in British Columbia.

Trials

Recruiting or not yet

Trial sites

Trials with a site in Kelowna

13 trials, recruiting first

		Phase
Standardized Natural Psilocybin-assisted Psychotherapy for Tapering of Opioid Medication NCT05585229	Recruiting	Phase 2	University of British Columbia	2025-10-27
Solving SCI Pain: Pain Recovery Tools for SCI NCT07212725	Completed	Not applicable	University of British Columbia	2025-09-15
Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy NCT06568042	Completed	Phase 2	Eli Lilly and Company	2024-08-22
A Randomized, Controlled Study of Repeat Dose Sustained Release Lidocaine for Treatment of Chronic Scrotal Pain NCT05707208	Completed	Phase 2	Sustained Therapeutics Inc.	2023-03-21
Effects of Spinal Cord Injury Exercise Guidelines NCT04160858	Unknown status	Not applicable	University of British Columbia	2020-01-16
Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome NCT02858453	Unknown status	Phase 3	Aquinox Pharmaceuticals (Canada) Inc.	2016-07
Evaluation of Galcanezumab in the Prevention of Chronic Migraine NCT02614261	Completed	Phase 3	Eli Lilly and Company	2015-11-30
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina NCT01659580	Completed	Phase 3	Tasly Pharmaceuticals, Inc.	2012-08
Methadone Hydrochloride as First-Line Therapy in Treating Patients With Chronic Neuropathic Cancer Pain NCT00930332	Terminated	Phase 1	NCIC Clinical Trials Group	2010-06-17
A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy NCT01041859	Completed	Phase 3	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2009-12
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis-related Pain NCT00973141	Terminated	Phase 2	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2009-09-16
A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain NCT00973024	Terminated	Phase 2	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2009-09
An Open-label Extension Study With Flexible Dosing of Extended-release (ER) Tapentadol (CG5503) to Treat Patients With Moderate to Severe Chronic Pain NCT00487435	Completed	Phase 3	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2007-06

Facilities listed in the registry

University of British Columbia (2 trial sites)
For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician. (1 trial site)
OCT Research ULC (1 trial site)
BCCA - Cancer Centre for the Southern Interior (1 trial site)
Dr. Petr Polasek, MD, Office of (1 trial site)
Site 1013 (1 trial site)
University of British Columbia - Okanagan Campus (1 trial site)
Kelowna General Hospital Clinical Research Department (1 trial site)

Facility names are as entered by study registrants. This is not a clinic directory.

Map

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status.